Evidence map›Paper›PMID 26254143›Full record

ArticleClinical oral investigations2016

Salivary and serum interleukin-6 levels in proliferative verrucous leukoplakia.

Leticia Bagan, Guillermo T Sáez, M Carmen Tormos, Carlos Labaig-Rueda, Judith Murillo-Cortes, Jose V Bagan

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical oral investigations, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 4 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Salivary Immune and Endocrine Biomarkers in Skin and Mucocutaneous Diseases.Advances in experimental medicine and biology · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Leticia BaganOral Medicine Department, Valencia University, Valencia, Spain.
Guillermo T SáezDepartment of Biochemistry, School of Medicine, University of Valencia, Valencia, Spain.
M Carmen TormosDepartment of Biochemistry, School of Medicine, University of Valencia, Valencia, Spain.
Carlos Labaig-RuedaDepartment of Stomatology, Valencia University, Valencia, Spain.
Judith Murillo-CortesService of Stomatology and Maxillofacial Surgery, University General Hospital, Avda Tres Cruces s/n, 46014, Valencia, Spain.
Jose V BaganOral Medicine Department, Valencia University, Valencia, Spain. bagan@uv.es.
Universitat de València · ESHospital General Universitario De Valencia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytokines and chemokines have been analysed in patients with oral squamous cell carcinoma and potentially malignant disorders. We selected interleukin-6 (IL-6) because it is a multifunctional interleukin reported to be altered in potentially malignant oral disorders and in malignant lesions. To date, this has not been evaluated or tested in proliferative verrucous leukoplakia (PVL), however.

objectivesThis study aimed to analyse the differences in serum and saliva IL-6 levels among patients with PVL, oral squamous cell carcinoma (OSCC) and healthy controls and to examine the relationship between salivary IL-6 levels and the extent of the verrucous area.

methodsUsing an enzyme-linked immunosorbent assay, we determined the serum and saliva IL-6 levels in three groups: 20 patients with PVL, 20 with OSCC and 20 healthy controls.

resultsThere were significant (p < 0.01) differences in the serum and saliva IL-6 levels among the three groups and among the three grades of extent of the verrucous areas (p = 0.01). In the OSCC group, there was a significant difference in the saliva IL-6 levels between patients with and without lymph node metastasis at diagnosis (p = 0.02).

conclusionsWe found that patients with OSCC had the highest salivary and serum IL-6 levels, while PVL had lower values than OSCC, but higher than the controls, and these altered levels were associated with the extent of the verrucous areas. CLINICAL RELEVANCE: Salivary and plasma IL-6 are altered in patients with PVL, with more extensive verrucous areas being associated to the highest IL-6 levels. This could be a significant tool for monitoring patients with PVL, their progression to more advances stages and their recurrences.

Indexed as

Carcinoma, Squamous CellCase-Control StudiesHumansInterleukin-6LeukoplakiaLeukoplakia, OralMouth NeoplasmsNeoplasm Recurrence, LocalSalivaInterleukin-6Interleukin-6Proliferative verrucous leukoplakia

Identifiers

PMID26254143
OpenAlexW1067943445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.